These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22868923)

  • 1. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
    Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
    Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
    Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
    Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. bcl-2 protein is strongly expressed in post-transplant lymphoproliferative disorders.
    Chetty R; Biddolph S; Kaklamanis L; Cary N; Stewart S; Giatromanolaki A; Gatter K
    J Pathol; 1996 Nov; 180(3):254-8. PubMed ID: 8958801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
    Capello D; Berra E; Cerri M; Gaidano G
    Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.
    Murray PG; Swinnen LJ; Flavell JR; Ragni MV; Baumforth KR; Toomey SM; Filipovich AH; Lowe D; Schnell CS; Johl J; Gulley M; Young LS; Ambinder RF
    Hum Pathol; 2001 Sep; 32(9):963-9. PubMed ID: 11567226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
    J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders.
    Smir BN; Hauke RJ; Bierman PJ; Gross TG; d'Amore F; Anderson JR; Greiner TC
    Lab Invest; 1996 Oct; 75(4):575-88. PubMed ID: 8874388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders are not associated with IgG4 sclerosing disease.
    Cathro HP; Bullock GC; Bonatti H; Meriden Z; Cook S; Aguilera N
    Transpl Infect Dis; 2014 Dec; 16(6):897-903. PubMed ID: 25298125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.